Xspray Pharma’s Nomination Committee for the Annual General Meeting 2022

Regulatory press release 2021-10-15

Xspray Pharma AB (Nasdaq Stockholm: XSPRAY) publishes the Nomination Committee’s composition for the Annual General Meeting in 2022.

The Nomination Committee, which has been appointed in accordance with the principles adopted by the Annual General Meeting on 20 May 2021, consists of:

Gillis Cullin, appointed by Östersjöstiftelsen
Anders Bladh, appointed by Ribbskottet AB
Caroline Sjösten, appointed by Swedbank Robur Fonder
Jannis Kitsakis, appointed by AP4
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB

The Nomination Committee shall, before the Annual General Meeting 2022, prepare proposals for the election of Chairman and other members of the Board of Directors, the election of Chairman of the Annual Meeting, election of auditors, the determination of fees and matters pertaining thereto.

Shareholders who wish to submit proposals to the Nomination Committee prior to the Annual General Meeting on May 19, 2022, can do so via e-mail to generalmeeting@xspray.com before March 31, 2022.

For further information about the nomination committee, please contact:
Anders Ekblom, Chairman of the Board of Directors, Xspray Pharma AB
Email: anders.ekblom100@gmail.com

About Xspray Pharma

Xspray Pharma AB (publ) is a pharma company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 68 in the beginning of 2021. The company’s leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com